Cara Therapeutics (NASDAQ:CARA) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.07, Fidelity Earnings reports. The firm had revenue of $5.53 million for the quarter, compared to analysts’ expectations of $3.35 million.
CARA stock traded up $2.05 during midday trading on Wednesday, reaching $19.48. 1,472,176 shares of the company’s stock traded hands, compared to its average volume of 591,725. The stock has a market cap of $684.83 million, a price-to-earnings ratio of -10.47 and a beta of 2.87. Cara Therapeutics has a fifty-two week low of $11.46 and a fifty-two week high of $24.30.
A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 21st. BidaskClub cut shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 1st. Canaccord Genuity set a $25.00 price target on shares of Cara Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 20th. Piper Jaffray Companies set a $27.00 price target on shares of Cara Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 20th. Finally, Janney Montgomery Scott assumed coverage on shares of Cara Therapeutics in a research report on Thursday, December 20th. They set a “buy” rating and a $13.36 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $24.03.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Featured Article: Market Capitalization
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.